Attention was on Brussels, where a two-day meeting of European leaders has turned into four, with talks scheduled to resume in the afternoon
European stocks edged higher on Monday, with top leaders still negotiating on a rescue fund to bolster the economic response to the coronavirus.
In midmorning action, the Stoxx Europe 600, 1.00% traded 0.2% higher, overcoming a weaker start.
The German DAX, 1.75%, French CAC 40, 1.23% and U.K. FTSE 100, 0.56% also saw cautious moves.
After the S&P 500, +0.84% advanced 1.25% last week, futures on the Dow Jones Industrial Average, 0.65% slipped 146 points.
Attention was on Brussels, where a two-day meeting of European leaders has turned into four, with talks scheduled to resume in the afternoon.
Reports suggest that the leaders may agree on €390 billion ($445.99 billion) worth of grants on a fund that could be worth between €700 billion ($800.49 billion) and €750 billion ($857.67 billion).
That the summit heads into its fourth day could be a good sign. It suggests a deal may be possible at this summit already, at least on parts of what is on the table, said Florian Hense, European economist at Berenberg Bank.
In addition to the Brussels summit, EU negotiators are in London on Monday for a fifth set of negotiations on the U.K.’s exit from the trading bloc.
The coronavirus also is a focus, with U.K. Prime Minister Boris Johnson over the weekend likening a second lockdown to a nuclear deterrent. U.S. coronavirus numbers have plateaued, with new cases of about 64,000 on Sunday.
GlaxoSmithKline, 0.01% shares slipped 1% after agreeing to pay CureVac as much as £866 million, in a deal that nets the U.K. pharmaceutical giant a nearly 10% stake in the German biotech known for its vaccines capabilities.
AstraZeneca, -1.05% rose 2% ahead of the publication of a study expected in The Lancet on the coronavirus vaccine from the University of Oxford it will distribute.
Shares of Enzymatica, -5.50% surged 77% as the company said preliminary results show the ability of the mouth spray ColdZyme, in vitro, to deactivate SARS-CoV-2, the virus causing the COVID-19 pandemic.
Philips, -0.40% rose nearly 5% after better-than-forecast second-quarter earnings.
UBI Banca, 2.23% shares shot up 13% as Intesa Sanpaolo added a cash component to its takeover offer.
The articles are for information purposes only and Precise Investors shall not be held responsible for any errors, omissions or inaccuracies within it. Any rules or regulations mentioned within the website are those relevant at the time of publication and may not be the most up-to-date.
Precise Investors does not endorse any of the products or services that appear on it or are linked to it and are not liable for any action that you may take as a result of the content of this website, or losses or damage you may incur doing so.
There is no obligation to purchase anything but, if you decide to do so, you are strongly advised to consult a professional adviser before making any investment decisions.
Please remember that investments of any type may rise or fall and past performance does not guarantee future performance in respect of income or capital growth; you may not get back the amount you invested.